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A bstract. Recently, we described the cloning and expression of a human cDNA which is the homologue to P600, 
a gene transcribed by mouse Th2 clones. Based on its activities on human monocytes and B cells this gene was 
designated IL-13. In the present study we investigated the effects of IL-13 alone or in combination with IL-4, IFN-y, 
or IL-10 on human monocytes. IL-13 induced significant changes in the phenotype of monocytes. Like IL-4, it 
enhanced the expression of CD11b, CD11c, CD18, CD29, CD49e (VLA-5), class II MHC, CD13, and CD23, 
whereas it decreased the expression of CD64, CD32, CD16, and CD14 in a dose-dependent manner. IL-1 3 induced 
up-regulation of class II MHC Ag and its down-regulatory effects on CD64, CD32, and CD16 expression were 
prevented by IL-10. IFN-7  could also partially prevent the IL-13-induced down-regulation of CD64, but not that 
of CD32 and CD16. However, IL-13 strongly inhibited spontaneous and IL-10- or IFN-y-induced ADCC activity 
of human monocytes toward anti-D coated Rh+ erythrocytes, indicating that the cytotoxic activity of monocytes 
was inhibited. Furthermore, IL-13 inhibited production of IL-1 a, IL-1/3, IL-6, IL-8, IL-10, IL-12 p35, IL-12 p40, 
macrophage inflammatory protein-1 a, granulocyte/macrophage-CSF, granulocyte-CSF, IFN-a, and TNFa by mono­
cytes activated with LPS. In contrast, IL-13 enhanced the production of IL-1 ra by these cells. Similar results on 
cytokine production were observed or have been obtained with IL-4. Thus IL-13 shares most of its activities on 
human monocytes with ILf4, but no additive or synergistic effects of IL-4 and IL-13 on human monocytes were 
observed, suggesting that these cytokines may share common receptor components. Taken together, these results 
indicate that IL-13 has anti-inflammatory and important immunoregulatory activities. Journal of Immunology, 
1993, 151: 6370.
A ctivated T cells secrete a number of biologically active polypeptides, which regulate the prolifera­tion, differentiation, and function of cells partici­
pating in immune responses against Ag (1). T cells pro­
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ducing IL-2, IL-3, IL-4, IL-5, IL-6, IL-10, IFN-y, GM- 
CSF,3 and TNF/LT simultaneously after antigenic or 
polyclonal stimulation have been described in both mouse 
and man (2-4). These T helper cells were designated ThO 
cells to distinguish them from the more specialized Thl and
2 Address correspondence and reprint requests to Dr. René de Waal Malefyt, 
DNAX Research institute, Human Immunology Department, 901 California 
Ave, Palo Alto, CA 94303-1104.
3 Abbreviations used in this paper: GM, granulocyte/macrophage; G, granu­
locyte; USA, human serum albumin; MIP, macrophage inflammatory protein; 
PCR, polymerase chain reaction; nt, nucleotide; ADCC, antibody-dependent 
cell-mediated cytotoxicity.
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Th2 subsets (5). Murine Thl cells produce IL-2, IFN-y, 
TNF/LT, IL-3, and GM-CSF which support their function 
as regulatory and effector cells in cellular immune re­
sponses such as delayed-type hypersensitivity, whereas 
Th2 cells produce IL-4, IL-5, IL-6, IL-10, IL-3, and GM- 
CSF which make them suitable for providing help to B cells 
in the production of immunoglobulins of different isotypes 
(6, 7). In humans, T cell clones with restricted cytokine 
production profiles have also been isolated from patients 
with infectious or allergic diseases (8-12). Although these 
type of clones resembled murine Thl and Th2 clones, there 
were some differences. Depending on their mode of acti­
vation, Thl clones generally could still produce low quan­
tities of IL-4, whereas Th2 clones were able to produce low 
to normal quantities of IFN-y (10-12). However, a clear 
imbalance in the production ratios of IL-4 and IFN-y by 
Th2 clones was observed after antigenic stimulation (12). 
Therefore we defined human T cell clones which produce 
high levels of IFN-y and no or low levels of IL-4 Thl-“like” 
cells and T cell clones which produce no or low levels of 
IFN-y and high levels of IL-4 Th2-“like” cells (10-12). 
Furthermore, IL-10 which is exclusively produced by ThO 
and Th2 T cell subsets in the mouse is synthesized by ThO, 
Thl-“like,” and Th2-“like” subsets in humans (13).
Recently, we and others (14) cloned the human cDNA  
homologue of P600, a mRNA which is transcribed by ac­
tivated mouse Th2 clones (15,16) and expressed the mouse 
and human cDNA clones in Escherichia coli (17). Both 
human and mouse P600 proteins were biologically active 
and affected human monocyte and B cell functions. There­
fore, we proposed that this novel cytokine be designated 
IL-13 (17). Human IL-13 is a unglycosylated protein of 132 
amino acids with a molecular mass of 10 kDa. Both human 
and mouse IL-13 induced proliferation of the human pre- 
myeloid cell line TF1. In addition, IL-13 was shown to 
induce changes in the morphology of the adherent fraction 
of human PBL which contained predominantly monocytes. 
These cells formed long cellular processes and adhered 
strongly to the substrate, IL-13 also induced changes in the 
phenotype of human monocytes and human B cells by up- 
regulating class II MHC expression and inducing the ex­
pression of the low affinity receptor for IgE (FceRII, CD23) 
(17, 18). Furthermore, IL-13 acted on human B cells by 
inducing proliferation and immunoglobulin production. In 
particular, IL-13 induced human B cells to switch to e and 
produce IgG4 and IgE in the presence of T cell clones, T 
cell membranes, or CD40 ligand (18, 19). These results 
indicated that many of the presently known biologic 
activities of IL-13 are shared with IL-4.
In this study the biologic activities of mouse and human 
IL-13 on human monocytes were further characterized and 
compared with those of IL-4, IL-10 and IFN-y, other cy­
tokines with stimulatory of inhibitory actions on human 
monocytes. IL-13 induced dramatic changes in the pheno­
type of human monocytes and inhibited the production and 
expression of IL -la, IL-1/3, IL-6, IL-8, IL-10, IL-12 p35, 
IL-12 p40, GM-CSF, G-CSF, M IP-la, and TNFa after ac­
tivation by LPS, whereas it enhanced the production 
of IL-lra. These results indicate that IL-13 has anti­
inflammatory activities and may play an important 
regulatory role in immune responses.
Materials and Methods
Isolation and culture of human monocytes
Human monocytes were isolated from peripheral blood of 
healthy donors by centrifugation over Ficoll-Hypaque and 
adherence to plastic. Briefly, 100 X  106 PBMNC were 
plated on a 100-mm tissue culture dish in YssePs medium 
(20) supplemented with HSA and 1% pooled human A B+ 
serum and incubated at 37°C for 30 min. This culture me­
dium was endotoxin free as determined by the Limulus 
amoebocyte lysate assay (< 0 .2  ng/ml of endotoxin). Sub­
sequently, nonadherent cells were removed by extensive 
washing and cultured in Yssel’s medium with HSA and 1% 
pooled human AB serum as indicated. Alternatively, highly 
purified human peripheral blood monocytes were obtained 
from 500 ml of blood of normal donors by centrifugal 
élutriation as described previously (21, 22). Mononuclear 
cells were isolated by density centrifugation in a blood 
component separator, followed by fractionation into lym­
phocytes and monocytes. The monocyte preparation was 
>95% pure, as judged by nonspecific esterase staining, and 
contained more than 98% viable cells. These monocytes 
were cultured in YssePs medium with HSA and 1% pooled 
human A B + serum at a concentration of 4 X 106 cells/ml 
in Teflon bags (Jansen MNL, St. Niklaas, Belgium), which 
prevented adhesion of these cells. After culture for the 
times indicated, monocytes were collected and analyzed for 
cell surface expression by indirect immunofluorescence or 
analyzed for lymphokine gene expression by Northern and 
PCR analysis. In addition, monocyte culture supernatants 
were collected for determination of IL-la, IL-1|3, IL-6, 
IL-8, IL-10, TNFa, M IP-la, GM-CSF, G-CSF, and IL-lra 
production after activation of these cells by LPS (E. coli 
0127:B8) (Difco, Detroit, MI) at 1 ¡xg/ml. The viability of 
the cells after culture always exceeded 95% as determined 
by trypan blue exclusion.
Reagents
Human and mouse rIL-13 were expressed in E . coli as in­
soluble aggregates of glutathione-S-transferase fusion pro­
teins, extracted by centrifugation, solubilized, and sub­
jected to renaturation before digestion with thrombin to 
remove the N-terminal fusion part (23). Subsequently, pro­
teins were purified by cation exchange and gel filtration 
chromatography, which resulted in active human and 
mouse IL-13 as described previously (17). Purified human
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rIL-10, rIL-4, and rIFN-y were provided by Schering- 
Plough Research (Bloomfield, NJ), The neutralizing anti- 
IL-4 mAb 25D2 (24) and anti-IL-10 mAb 19F1 (25) were 
described previously. The following mAb were used for 
immunofluorescence studies on the expression of cell sur­
face markers: SPV-L7 (C D lla) (26), Bear-1 (CD lib )  (27), 
CLB FcR gran-1 (CD16) (28), mAb 25 (CD23) (29), IV.3 
(CD32) (30), 32.2 (CD64) (31), Q5/13 (HLA-DR/DP) (32), 
PdV5.2 (HLA-DR/DP/DQ) (33), SAM-1 (VLA-5, CD49e) 
(34), and L307 (B7) (35). IOM13 (CD13) and CD29 were 
purchased from AMAC, Inc (Westbrook, ME). Leu-M3 
(CD 14), Leu-M5 (CDllc), and L130 (CD18) were 
obtained from Becton-Dickinson (San Jose, CA).
Probes
Oligonucleotides used for Southern analysis of IL-la, IL- 
lß , IL-6, GM-CSF, G-CSF, and ß-actin PCR products and 
DNA fragments used for detection of IL-8, IL-10, TGF-ß, 
and ß-actin mRNA have been described (36). The follow­
ing oligonuclotides were used to detect IFN-a, 5'- 
TTCTGGCTGTGAGG AAATACT-3' (nt 360-378) (37); 
IL-12 p35, 5'-AATGGGAGTTGCCTGGCCTC-3 ' (nt 
488-507) (38); IL-12 p40, 5 '-TAAGACCTTTCTAA- 
GATGCGAGGCC-3 ' (nt 417-441) (38).
mRNA isolation and northern analysis
Total RNA was isolated from 20 X 106 monocytes by the 
guanidinium thiocyanate-CsCl procedure (39). For North­
ern analysis, 5 /xg total RNA per sample was separated 
according to size on 1% agarose gels containing 6.6% form­
aldehyde, transferred to Nytran nylon membranes (Schlei­
cher & Schuell, Keene, NH), and hybridized with probes, 
labeled to high specific activity ( > 108 cpm/mg) by the 
hexamer labeling technique (40). Filters were hybridized, 
washed under stringent conditions, and developed as 
described previously (41),
PCR analysis
One microgram of total RNA was reverse transcribed using 
oligo(dT)12_18 as primer (Boehringer Mannheim, India­
napolis, IN) and superscript reverse transcriptase (GIB CO 
BRL, Gaithersburg, MD) according to the procedure of 
Krug and Berger (42) in a 20-/li1 reaction. Two microliters 
of reverse transcript (equivalent to 100 ng of total RNA) 
was used directly for each amplification reaction. Condi­
tions for PCR were as follows: in a 50-juri reaction, 25 nmol 
of each primer, 125 /iM each of dGTP, dATP, dCTP, and 
dTTP (Pharmacia, Uppsala, Sweden), 50 mM KC1,10 mM 
Tris-HCl, pH 8.3, 1.5 mM MgCl2, 1 mg/ml gelatin, 100 
mg/ml nonacetylated BSA, and 1 U of Vent DNA polym­
erase (New England Biolabs, Beverly, MA), Primers used 
to amplify IL-la, IL-lß, IL-6, GM-CSF, G-CSF, and 
ß-actin have been described previously (36). The following
primers were also used: IFN-a sense primer, 5'-GCT- 
GAAACCATCCCTGTC-3' (nt 161-178) (37); IFN-a an­
tisense primer, 5' -CTGCTCTGACAACCTCCCAG-3' (nt 
450-430) (37); IL-12 p35 sense primer, 5'-CTTCAC- 
CACTCCCAAAACCTG-3' (nt 281-302) (38); IL-12 p35 
antisense primer, 5' -AGCTCGTCACTCTGTCAATAG-3' 
(nt 813-792) (38); IL-12 p40 sense primer, 5'- 
CATTCGCTCCTGCTGCTTCAC-3' (nt 337-358) (38); 
IL-12 p40 antisense primer, 5'-TACTCCTTGTTGT- 
CCCCTCTG-3' (nt 603-582) (38). Reactions were incu­
bated in a Perkin-Elmer Cetus DNA Thermal cycler 9600 
for 25 cycles (denaturation 30 s 94°C, annealing 30 s 55° C, 
extension 60 s 72°C). Forty microliters of each reaction was 
loaded on 1% agarose gels in TAE buffer and PCR products 
were visualized by ethidium bromide staining. Subse­
quently, gels were denatured in 0.5 M NaOH, 1.5 M NaCl, 
neutralized in 1 M ammonium acetate, and transferred to 
Nytran nylon membranes. Membranes were prehybridized 
in 6 X SSC, 1% SDS, 10 X Denhardt’s solution (0.2% 
Ficoll, 0.2% polyvinylpyrrolidone, 0.2% BSA, pentax frac­
tion V) and 200 mg/ml E. coli tRNA (Boehringer, Mann­
heim, FRG) for 4 h at 55°C. Oligonucleotide probes (200 
ng), specific for a sequence internal to the primers used in 
the amplification, were labeled at the 5' end by T4 poly­
nucleotide kinase (New England Biolabs) and [y-32P]ATP 
(Amersham, Arlington Heigths, IL) as described (36). 
Probes were separated from nonincorporated nucleotides 
by passage over a Nick column (Pharmacia, Uppsala, Swe­
den) and added to the hybridization mixture. After hybrid­
ization for 12 h at 55°C, filters were washed in 0.1 X SSC 
(1 X SSC: 150 mM NaCl, 15 mM sodium citrate, pH =  
7.0), 0.1% SDS at room temperature, and exposed to Kodak 
XAR-5 films for 1 to 2 h. In addition, signals were 
quantified on a Molecular Dynamics phosphor-imager 
(Molecular Dynamics, Sunnyvale, CA)
Lymphokine determinations
The production of cytokines by monocytes was determined 
in culture supernatants by cytokine-specific ELISA which 
were either obtained commercially or described previously. 
The cytokine-specific ELISA and their sensitivities were: 
IL-la Endogen (Boston, MA) (50 pg/ml), TNFa Endogen 
(Boston, MA) (10 pg/ml), IL-lß Cistron (Pine Brook, NJ) 
(20 pg/ml), IL-6 Genzyme (Boston, MA) (0.313 ng/ml), 
IL-8 R&D Systems (Minneapolis, MN) (4.7 pg/ml), G-CSF 
R&D Systems (Minneapolis, MN) (7.2 pg/ml), IL-lra 
R&D Systems (Minneapolis, MN) (12.5 pg/ml), MIP-la 
R&D Systems (Minneapolis, MN) (2.0 pg/ml), GM-CSF 
(43) (50 pg/ml), and IL-10 (25) (75 pg/ml).
Immunofluorescence analysis
Cells (105) were incubated in V bottom microtiter plates 
(Flow Laboratories, McLean, VA) with 10 jul of purified 
mAb (1 mg/ml) for 30 min at 4°C. After two washes with
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FIGURE 1. Effect of cytokines on the 
expression of cell surface Ag by mono­
cytes. Human monocytes were cul­
tured in medium, IL-4 (400 U/ml), 
IL-10 (200 U/ml), or IFN-y (100 U/ml) 
in the (□) absence or the (■) presence 
of IL-13 (50 ng/ml) for 120 h, and the 
expression of cel! surface Ag was de­
termined by indirect immunofluores­
cence. The mean changes in mean 
fluorescence intensity ± SD of six in­
dividual experiments are given in 
parentheses.
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PBS containing 0.02 mM sodium azide and 1% BSA 
(Sigma), the cells were incubated with 1:40 dilution of 
FITC-labeled F(ab')2 fragments of goat anti-mouse anti­
body (TAGO, Inc. Burlingame, CA) for 30 min at 4°C. 
After three additional washes, the labeled cell samples 
were analyzed by flow microfluometry on a FACScan 
(Becton Dickinson, Sunnyvale, CA).
ADCC
ADCC activity of cultured human monocytes against an­
tibody coated rhesus positive human erythrocytes was 
performed as previously described (44),
Results
IL-13 and IL-4 induce identical changes in monocyte 
surface Ag expression
Previously, we described that both mouse and human IL-13 
induced expression of CD23 (FceRIl) and up-regulated the 
expression of class II MHC Ag on human monocytes. The 
effects of IL-13 on the expression of a larger panel of cell 
surface Ag was examined here. A  representative experi­
ment shown in Figure 1 indicated that IL-13 affected the
expression of multiple cell surface molecules belonging to 
different supergene families, The mean changes in fluo­
rescence intensity by IL-13 from six independent experi­
ments are given in parentheses. IL-13 enhanced the ex­
pression of several members of the integrin superfamily of 
adhesion molecules. The expression of the subunits C D llb  
(C3bi receptor, Mac-1), C D llc  (gpl50), and VLA-5 (FNR) 
as well as their respective /3 subunits CD 18 (/32) and CD29 
(j31, VLA-b) was up-regulated by IL-13. The expression of 
other members of this family, including C D lla  (LFA-1), 
VLA-2 (CD49b), VLA-3, VLA-4 (CD49d), VLA-6 
(CD49f), J33 (CD61) and j34 was not significantly affected 
by IL-13 (not shown).
IL-13 enhanced the expression of class II MHC Ag (Fig. 
1). The expression of HLA-DR, HLA-DP, and HLA-DQ 
was up-regulated by IL-13. Expression of other members 
of the immunoglobulin superfamily including class I MHC, 
CDlla(LFA-l), CD54 (ICAM-1), ICAM-2, and CD58 
(LFA-3) was not affected by IL-13 (not shown).
IL-13 modulated the expression of the various Fc re­
ceptors on monocytes. The expression of CD64 (FcyRI), 
CD32 (FcyRII), and CD 16 (FcyRIII) on human monocytes 
was strongly down-regulated by IL-13 (Fig. 1). In contrast,
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Table I
IL-13 acts independently of !L-4a
mAb Medium
IL-13 IL-4
+ anti-IL-4 + anti-IL-4
Control 3b 5 6 5 3
MHC class II 443 1904 1845 2084 220
CD23 3 99 79 89 8
CD14 222 97 83 80 444
a Monocytes were incubated with medium, IL-13 (50 ng/ml), or IL-4 (400 
U/ml) in the absence or presence of neutralizing anti-IL-4 mAb 25D2 (10 
pg/ml) at 37°C for 120 h; and expression of HLA-DR/DP (Q5/13), CD23 (mAb 
25), and CD14 (Leu-M3) was determined by indirect immunofluorescence. 
faMean fluorescence intensity (channel number).
as has already been demonstrated previously, IL-13 in­
duced the expression of CD23 (FceRII) (17). In addition, 
IL-13 up-regulated the expression of CD 13 (aminopepti- 
dase N) and down-regulated the expression of CD 14 (Fig. 
1). No effect of IL-13 was detected on the expression of 
CD25, CD33, and CD44 (not shown).
IL-4 up-regulated expression of C D llb , C D llc, CD18, 
VLA-5, CD29, class II MHC, CD13, and CD23 and in­
hibited the expression of CD16, CD32, CD64, and CD 14 
on human monocytes to the same extend as did IL-13 (Fig. 
1). Changes in the expression of these markers by IL-13 or 
IL-4 were dose-dependent (not shown). Taken together, 
these data indicate that the IL-13-induced changes in the 
expression of cell surface molecules are identical with those 
induced by IL-4 (Fig. 1). Interestingly, incubation of mono­
cytes with saturating concentrations of both IL-4 and IL-13 
did not result in additive or synergistic activities effects on 
the expression of the various cell surface molecules (Fig. 
1). To date, no evidence has been presented that monocytes 
are able to produce IL-4. However, to exclude the possi­
bility that IL-13 acted through the induction of IL-4 by 
monocytes or by few contaminating T cells, monocytes 
were incubated in the presence of IL-13 and a neutralizing 
anti-IL-4 mAb. As shown in Table I, the induction of CD23, 
down-regulation of CD 14 and up-regulation of class II 
MHC by IL-13 was not affected by the anti-IL-4 mAb. The 
anti-IL-4 mAb was effective because it completely inhib­
ited the effects of IL-4 in control experiments (Table I). 
Thus, IL-13 acts independently of IL-4.
IL-10 down-regulates lL-13-induced class I! MHC 
expression on human monocytes
To compare the effects of IL-13 with those of other cyto­
kines which modulate the monocyte phenotype, these cells 
were incubated with IL-10 or IFN-y in the absence or pres­
ence of IL-13, and the expression of cell surface Ag was 
analyzed. As shown in Figure 1, IL-10 or IFN-y alone did 
not significantly affect the expression of CD lib , C D llc , 
CD 18, CD 13, CD23, CD29, and VLA-5. In addition, IL-10 
or IFN-y did not affect the IL-13-induced increase in ex­
pression of these markers. IL-10 or IFN-y had also no effect
Table II
IL-10 inhibits constitutive, IL-I3-, IL-4-, and IFN-y-induced 
MHC class II expression on human monocytesa
Incubation
IL-10 (200 U/ml)
— +
Control 4°C 69b N D C
Medium 37°C 150 46
miL-13 212 73
hIL-13 197 81
IL-4 407 94
IFN-y 347 36
3 Elutriated monocytes were incubated In medium at 4°C or 37°C, mouse 
IL-13 (50 ng/ml), human IL-13 (50 ng/ml), IL-4 (400 U/ml), or IFN-y (100 U/ml) 
in the absence or presence of IL-10 (200 U/ml) in Teflon bags for 48 h; and 
expression of HLA-DR/DP was determined by indirect immunofluorescence.
h Mean fluorescence intensity (channel number).
c ND, not done.
on the expression of CD 14 and the IL-13-induced inhibition 
of CD 14 expression. However, IL-10 down-regulated not 
only the constitutive class II MHC Ag expression on mono­
cytes (36), but also inhibited strongly the IL-13-induced 
class II MHC expression. Similar data were obtained when 
highly purified monocytes isolated by elutriation and cul­
tured in Teflon bags were used (Table II). An increased 
expression of class II MHC Ag was observed after incu­
bation of monocytes in medium alone, which was com­
pletely prevented by IL-10. mIL-13, hIL-13, IL-4, and 
IFN-y all induced high levels of class II MHC expression 
which were blocked by IL-10 (Table II). Class II MHC 
expression induced by IFN-y was further enhanced by 
IL-13 (Fig. 1). Taken together, these results indicate that 
IL-13, IL-10, and IFN-y independently modulate the 
expression of monocyte surface Ag.
IL-13 inhibits monocyte FcyR surface expression 
and cytotoxicity
IFN-y, IL-4, and IL-10 are able to modulate the expression 
of FcyRI (CD64), FcyRII (CD32), and FcyRIII (CD16) on 
human monocytes. IFN-y and IL-10 enhance the expres­
sion of CD64, whereas IL-4 down-regulates the expression 
of CD64, CD32, and CD 16 (Fig. 1) (44-46). Addition of 
combinations of these cytokines to monocytes showed that 
IL-10 was able to prevent the IL-4-induced down- 
regulation in cell surface expression of all three FcyR (44) 
and that IFN-y partially restored the down-regulatory ef­
fects of IL-4 on CD64 expression (46). The effects of IL-10 
and IFN-y on IL-13-induced reduction in the expression of 
the various FcyR are shown in Figure 1. IL-10 prevented 
down-regulation of CD64, CD32, and CD 16 induced by 
IL-13. In addition, IFN-y could partially rescue IL-13- 
induced down-regulation of CD64, but did not affect the 
IL-13-induced down-regulation of CD32 and CD 16 
(Fig. 1).
The level of ADCC activity of human monocytes has 
been shown to correlate with the expression of FcyRI (47).
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FIGURE 2. IL-13 inhibits spontaneous, IFN-y- and IL-10- 
induced ADCC activity by monocytes. Elutriated monocytes 
(4 x 106/ml) were cultured in medium, IL-10 (200 U/ml) or 
IFN-y (100 U/ml) in the absence or presence of human (h) or 
mouse irn) IL-13 (50 ng/ml) for 40 h and ADCC activity 
against anti-D coated Rhesus* human erythrocytes was de­
termined at an effector/target ratio of 0.6, 0.4, 0.3, and 0.2.
Therefore, the effects of IL-13 on the functional activity of 
FcyRI on monocytes was determined by their ability to lyse 
anti-D opsonized human Rh+ erythrocytes. As shown in 
Figure 2 both human and mouse IL-13 were able to inhibit 
ADCC activity of monocytes cultured in medium alone. On 
the other hand, ADCC activity was enhanced when mono­
cytes were cultured in the presence of IFN-y or IL-10. In­
terestingly, IL-13 significantly inhibited these effects of 
IFN-y and IL-10 despite the fact that IFN-y and IL-10 par­
tially or completely reversed the inhibition of FcyRI ex­
pression (Fig. 1), indicating that there is no absolute cor­
relation between FcyRI expression and ADCC activity and 
that IL-13 affected the FcyR-mediated cytotoxicity also by 
other mechanisms.
IL-13 inhibits production of proinflammatory 
cytokines, chemokines and hematopoietic growth 
factors, but enhances IL-1 ra secretion
IL-lra. Monocytes are able to produce large amounts of 
IL-10 which can suppress the production of IL -la, IL-1/3, 
IL-6, IL-8, IL-10, GM-CSF, G-CSF, and TNFa in an au- 
toregulatory fashion (36). It is shown that LPS-activated 
monocytes produced high levels of IL-10 in this particular 
experiment (Table III). To exclude the effects of endog­
enous IL-10, monocytes were also activated by LPS in the 
presence of neutralizing anti-IL-10 mAb 19F1. As shown 
in Table III, activation of monocytes in the presence of 
anti-IL-10 mAbs resulted in strongly enhanced production 
of IL-la, IL-1/3, GM-CSF, G-CSF, TNFa;, and M IP-la, 
whereas IL-6 and IL-8 production was moderately en­
hanced. The production of IL-lra was sligthtly inhibited by 
anti-IL-10 mAb. To examine the effects of IL-4 and IL-13 
on cytokine production in the absence of endogenous IL- 
10, monocytes were activated by LPS in the presence of the 
anti-IL-10 mAb 19F1 and IL-4 or IL-13. As shown in Table 
III, IL-13 and IL-4 strongly inhibited the production of 
IL-1 a, IL-1/3, IL-6, GM-CSF, G-CSF, and TNFa. IL-4 also 
strongly inhibited the production of IL-8 and M IP-la under 
these conditions, whereas the inhibition of IL-8 and 
M IP-la by IL-13 was less pronounced.
The production of IL-lra was enhanced by IL-4 and 
IL-13 as compared with activation by LPS and anti-IL-10 
mAb, but was reduced in comparison with activation by 
LPS and either IL-4 or IL-13 in the absence of the 
anti-IL-10 mAb.
mRNA analyses by comparative PCR or Northern blot­
ting confirmed the effects IL-4, IL-13, IL-10, and anti- 
IL-10 on the production of most cytokines by LPS- 
activated monocytes at the level of gene expression as 
shown in Figures 3 and 4. Generally, a good correlation was 
observed between the levels of mRNA or amplified cDNA 
product and secreted proteins with exception of IL-1/3. LPS 
induced the expression of IL-10 mRNA, which was inhib­
ited by IL-4, IL-13, and IL-10. Activation of monocytes by 
LPS in the presence of anti-IL-10 mAb showed a strong 
increase in the expression of IL-10 mRNA as described 
previously (36), and under these conditions IL-4 and IL-13 
were able to strongly inhibit IL-10 mRNA expression (Fig.
The effects of IL-13 on the production of cytokines by 4). Levels of TGF/3 mRNA were not affected by activation
human monocytes was investigated next. Monocytes were of monocytes by LPS; and IL-4, IL-10, and IL-13 did not
activated by LPS and cytokine production was determined change this constitutive expression (Fig. 4).
in culture supernatants harvested after 20 h by cytokine- The expression of IFN-a, IL-12 p35, and IL-12 p40 by
specific ELISA. Activation of monocytes by LPS resulted monocytes was examined at the mRNA level by compara-
in the production of IL-la, IL-1/3, IL-6, IL-8, IL-10, tive PCR analyses. It is shown in Figure 3 that activation
G-CSF, TNFa, M IPla, and IL-lra (Table III). IL-13 of monocytes with LPS resulted in low levels of amplified
strongly inhibited the production of IL-la, IL-1/3, IL-6, 
IL-8, IL-10, G-CSF, and TNFa. As described previously,
IFN-a cDNA which was inhibited by IL-4, IL-13, and IL-
10. In addition, it is shown that activation in the presence
IL-4 and IL-10 also strongly inhibited the production of of anti-IL-10 resulted in enhanced expression of IFN-a- 
these cytokines (36, 48). Interestingly, IL-13, IL-4, and specific products which was also strongly inhibited by IL-4
IL-10 strongly inhibited the production of MIP-la-like and IL-13. Interesting, similar results were observed for the
IL-8, a member of the chemokine family (49, 50). In con- expression of IL-12 p35 and IL-12 p40. It is shown (Fig. 
trast, IL-13, IL-4, and IL-10 enhanced the production of 3) that IL-12 p35- and IL-12 p40-specific products were
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Table III
Effect o f IL-13, IL-4, and (L-10 on cytokine production by human monocytes
Activation
Cytokine production (ng/ml)0
IL-1 a IL-1 ß IL-lra IL-6 IL-8 IL-10 GM-CSF G-CSF TNFa MIP-la
Medium 4°C 0 0 0 2 0 0 0 0 0 0
Medium 37°C 0 0.2 41 15 187 0.9 0 0 0 0
LPS 0.49 3.9 348 1290 1260 30 0 7.0 1.8 115
LPS + IL-4 0.06 0.8 809 271 244 5.5 0 0.4 0 4.5
LPS + IL-13 0.05 0.3 1070 1 72 285 6.9 0 0.3 0 1.7
LPS + IL-10 0 0.3 555 64 146 ND 0 0.3 0 . 0.5
LPS -b anti-IL-10 6.72 21.9 259 2000 1630 ND 0.52 179 16.4 288
LPS + anti-IL-10 + IL-4 0.88 0.7 729 391 527 ND 0 1.1 0 25.3
LPS + anti-IL-10 + IL-13 0.51 2.0 732 846 1330 ND 0.05 1.0 0.9 114
a Human monocytes (4 X 106/ml), purified by centrifugal élutriation, were activated by LPS (1 pg/ml} in the presence of IL-4 (200 ll/m!), IL-13 (50 ng/ml), IL-10 
(200 U/ml), or anti-IL-10 mAb 19F1 (10 pg/ml) for 20 h; and production of cytokines was measured in culture supernatants by cytokine-specific ELISA. 
b ND, not determined.
the expression of IL-12 p35 and IL-12 p40 under these 
conditions.
detected when monocytes were activated by LPS in the motypic aggregation (56). In addition, IL-4 enhances class
presence of anti-IL-10 mAb. This indicates that IL-10 II MHC expression, inhibits ADCC activity, and cytokine
strongly down-regulates the expression of IL-12 and that production by LPS-activated monocytes (46, 48). How-
1L-12 p35 and IL-12 p40 are coordinately expressed in ever, because the activities of IL-13 could not be blocked
monocytes. In addition, IL-4 and IL-13 strongly inhibited by a neutralizing anti-IL-4 mAb, it is demonstrated that
IL-13 acts independently of IL-4.
IL-13 down-regulated the expression of CD 14. CD 14 
can function as a receptor for LPS and LPS-CD14 binding 
is increased in the presence of LPS binding protein, an 
unidentified serum protein (57). IL-4 also down-regulated 
the expression of CD14 as descibed (58, 59), IL-13 up- 
regulated the expression of CD 13 (aminopeptidase-N). It 
has been demonstrated that IL-4 increased the expression 
of CD13 on mature monocytes which correlated function­
ally with an enhanced leucine-aminopeptidase activity 
(60). It can be expected that IL-13 will also increase 
leucine-aminopeptidase activity and that the changes in 
surface expression of CD 13 and CD 14 are part of the gen­
eral monocyte-activating and differentiation-inducing 
characteristics of IL-13 and IL-4.
IL-13 up-regulated the expression of class II MHC Ag 
on human monocytes. The expression of HLA-DR, HLA- 
DP, and HLA-DQ was significantly increased by IL-13, 
IL-10 inhibited IL-13-induced class II MHC expression, 
which is in keeping with our previous observations 
indicating that IL-10 also inhibited constitutive, IL-4-,
Discussion
In the present study we determined the biologic activities 
of IL-13 on human monocytes. IL-13 affected the mor­
phology, phenotype, function, and cytokine production of 
monocytes. We described previously that incubation of 
monocytes with IL-13 induced strong adherence of these 
cells to plastic substrates and that their morphology 
changed to a dendritic appearance (17). In addition, ho- 
motypic aggregates of cells were observed. The finding that 
IL-13 up-regulated the expression of CD l ib , C D llc ,
CD18, VLA-5, and CD29, which are members of the in- 
tegrin superfamiliy, is compatible with the observed ag­
gregation of monocytes and changes in their morphology, 
inasmuch as CDllb/CD18 and CDllc/CD18 heterodimers 
are involved in cell-cell interactions, homotypic aggrega­
tion, adhesion to artificial substrates (34, 51-53), and bind 
fibrinogen (54). In addition, the a5/31 integrin VLA-5/
CD29 is the receptor for fibronectin, which is an abundant 
extracellular matrix protein involved in adhesion processes a°d IFN-y-induced class II MHC expression on human
(55). IL-13 did not induce changes in the expression of monocytes (61). 
other molecules involved in adhesion or cell-cell interac- The expression of the various Fc receptors for IgG and 
tion, e.g., CDlla, VLA-2, VLA3, VLA-4, VLA-6, /33, j34, IgE on monocytes is influenced by cytokines. CD64 
ICAM-1,1 CAM-2, LFA-3, MEL-14, and CD44, but it re- (FcyRI) expression is up-regulated by IFN-y and IL-10, but 
mains possible that other cell surface structures are in- inhibited by IL-4 (44—46, 62). Furthermore, IFN-y and
IL-10 are able to prevent the down-regulation of CD64 
induced by IL-4 (44, 46). IL-13, like IL-4, inhibited the
volved in the IL-13-induced changes in morphology and 
adherence.
It has to be noted that many of the effects of IL-13 on constitutive expression of CD64. This inhibitory effect was 
monocyte morphology, phenotype, function, and cytokine prevented by IL-10 and IFN-y. The expression of CD64 has
production are shared with IL-4. IL-4 also induces strong been shown to correlate with ADCC activity of monocytes
iadherence of monocytes, formation of processes, and ho- (47). Indeed ADCC activity of monocytes incubated with
Journal of Immunology 6377
V*
<$> <£> 
^  V  V
>  &  F<y V vX X - *
\ ?  V
N** ,N*
0>V ^  ^
s  *  -  *  /. x ^  ^ ^V  V  V
N*
y
pi<y <y v/- -  x ^ X r  X ^  O^ <£> ^V s V  \ /
V" - 'N*
^  <y
X*s> ^
-  /  ><y
4
&  &  &  r*  r * r *<,*» ^  <f>V  V  V
!L-1a W - - :
* f ; . :
IL-1ß
IL-6
IL-12 p35
JL-12 p40
GMCSF . -.; v i ry '- i:.
GCSF Ü Ä ^
IL -8
.. ƒ. . . s A kW *.•
/•>
IL-10
T G F ß
Actin
FIGURE 4. Effects of IL-13 on mRNA expression of IL-8, 
IL-10, and TGFß. Elutriated monocytes (4 X 106/ml) were 
activated by LPS (1 pg/ml) in the absence or presence of IL-4 
(200 U/ml), IL-13 (50 ng/ml), IL-10 (200 U/ml), or combina­
tions of these cytokines and anti-IL-10 mAb 19FI (10 pg/ml) 
for 20 h. Expression of ÎL-8, IL-10, TGF/3, and /3-actin was 
determined by Northern analysis.
IFNci
FIGURE 3. IL-13 inhibits mRNA expression of proinflam- 
matory cytokines and hematopoietic growth factors. Elutri­
ated monocytes (4 X 106/ml) were activated by LPS (1 pg/ml) 
in the absence or presence of IL-4 (200 U/ml), IL-13 (50 
ng/ml), IL-10 (200 U/ml), or combinations of these cytokines 
and anti-IL-10 mAb 19F1 (10 pg/ml) for 20 h. Expression of 
IL-1 a, IL-1/3, IL-6, IL-12 p35, IL-12 p40, GM-CSF, GCSF, 
IFNa, and /3-actin was determined on reverse transcribed 
mRNA by PCR amplification with cytokine-specific primers 
and detection of the reaction products by Southern analysis 
using internal probes.
IL-13 was strongly inhibited, indicating that IL-13 not only 
affected the phenotype but also the function of human 
monocytes. Interestingly, although IL-10 prevented the IL- 
13-induced down-regulation of CD64 expression, ADCC 
activity was still inhibited. This supports the notion that 
ADCC activity is not only determined by the levels of 
CD64 expression, but that additional, yet to be defined 
mechanisms play a role (44).
IL-13, like IL-4, also affected the expression of FcyRII
and FcyRIII. IL-13 down-regulated the expression of CD32 
and CD16 in a dose-dependent manner. However, IL-10, 
but not IFN-y, could block the IL-13-induced down- 
regulation of CD32 and CD16 on monocytes. These results 
indicate that the level of Fc receptor expression is highly 
regulated by cytokines.
Thus far IL-4 was the only cytokine known to induce the 
low affinity Fc receptor for IgE (CD23) on monocytes (63). 
However, recently it was shown that IL-13 also induced the 
expression of CD23 on monocytes (17). Here it is dem­
onstrated that the IL-13-induced expression of CD23 could 
be partially suppressed by IFN-y. Like IL-4, IL-13 induces 
the production of IgE by PBMC (18). In addition, IL-13 
initiates germline e transcription in purified sIgM+ B cells 
and induced switching to IgE production in the presence of 
costimulatory signals provided by activated T cell clones, 
T cell membranes, or transfectants expressing the CD40 
ligand (18, 19). IgE production is modulated by various 
cytokines, including soluble CD23, which have either en­
hancing or inhibitory effects (64). The effects of IL-13 and 
IFN-y on the expression of CD23 by human monocytes fit 
well within this concept.
IL-13 strongly inhibited the production of inflammatory 
cytokines, hematopoietic growth factors, and chemokines 
by LPS-activated monocytes. These activities are shared 
with both IL-4 and IL-10 (36, 48, 65-68). These results
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further extend the observation that IL-13 inhibits the se­
cretion of IL-6 by LPS-activated PBMC (14). Monocytes 
produce IL-10 after activation (36). Therefore it is impor­
tant to study the effects of IL-4 and IL-13 on cytokine 
production in the absence of endogenously produced IL-10. 
Addition of a neutralizing anti-IL-10 mAb during the ac­
tivation indeed resulted in strongly enhanced production of 
these cytokines. It is shown that IL-13, IL-4, and IL-10 
strongly inhibited the production of the proinflammatory 
cytokines IL-la, IL-1/3, IL-6, IL-8, TNFa, and MIP-la. 
The inhibition of IL-la, IL-6, and IL-8 secretion by IL-13 
was observed at both protein and steady state mRNA levels, 
whereas the inhibition of IL-1/3 was more pronounced at the 
protein level. This indicated that the regulation of IL-ip 
expression by cytokines also occurs post-transcriptionally, 
as described by Donnelly et al. (69). Of the proinflamma­
tory cytokines, IL-8 is a member of the chemokine a sub­
family and chemoattracts and activates neutrophils, 
whereas MIP-la is a member of the chemokine j3 sub­
family which has chemoattractive and activation activities 
on monocytes and T cells (49, 50). On the other hand, IL-4, 
IL-13, and IL-10 enhance the production of IL-lra by LPS- 
activated monocytes. IL-lra is a competitive inhibitor of 
IL-la and IL-1/3 and acts by binding to type I and type II 
IL-1 receptors without activating them (70,71). It has been 
described that IL-4 induces IL-lra by monocytes in vitro 
and in vivo (72-75). Through the inhibition of IL-1 ac­
tivities, IL-lra has been shown to possess anti­
inflammatory activities in acute and chronic inflammation 
(76). Taken together, these data indicate that IL-13, IL-4, 
and IL-10 by inhibiting the production of proinflammatory 
cytokines and induction of IL-lra may have strong anti­
inflammatory activities. IL-13 also inhibited the production 
of the hematopoietic growth factors GM-CSF and G-CSF. 
This inhibition occurred at the level of gene expression. In 
addition it is shown that IL-13, like IL-4 and IL-10, in­
hibited the expression of IFN-a mRNA. This further 
illustrates the immunoregulatory properties of IL-13.
IL-13, like IL-4, inhibited the production of IL-10 
mRNA expression. Inhibition of IL-10 production by these 
Th2 cytokines may play a role in the establishment of 
chronic disease states because IL-10 has been identified as 
a general immune suppressor by down-regulating the pro­
duction of inflammatory cytokines, class II MHC expres­
sion on monocytes and T cell and NK cell responses (77).
Recently, it has been described that IL-12, a heterodi- 
meric cytokine composed of 35-kDa and 40-kDa polypep­
tides is produced by EBV-transformed B cell lines and 
Staphylococcus aureus Cowan I-activated monocytes (78). 
Here, we have shown that monocytes activated by LPS in 
the presence of neutralizing anti-IL-10 mAb can also tran­
scribe IL-12 p35 and IL-12 p40 mRNA and that this ex­
pression is strongly inhibited by IL-13, IL-4, and IL-10. 
The expression of IL-12 p40 chain mRNA seemed to be
more abundant than IL-12 p35 in accordance with data from 
D ’Andrea et al. (78). IL-12 has been shown to induce and 
enhance the expression of IFN-y by T cells and NK cells 
(79). The inhibitory effects of IL4, IL-13, and IL-10 on the 
production of IL-12 could play a role in the inhibitory ef­
fects of these cytokines on the production of IFN-y, a pos­
sibility which we are currently investigating. Inhibition of 
IL-12 by IL-4, IL-13, and IL-10 could also affect the cross­
regulation of Thl and Th2 subsets because IL-12 has re­
cently been shown to play a role in the development of 
Thl cells (80, 81).
IL-13 shares many of its activities with IL-4. Both cy­
tokines induce similar changes in cell surface phenotype, 
morphology, function, and cytokine production by human 
monocytes. Adding combinations of saturating amounts of 
IL-4 and IL-13 to monocytes resulted in identical changes 
in phenotype as compared with those induced by either 
cytokine alone. In addition, IL-13, like IL-4, is able to in­
duce the production of IgB by human B cells (18, 19). 
However, unlike IL-4, IL-13 does not support the prolif­
eration of PHA blasts or T cell clones (R. de Waal Malefyt, 
unpublished data) nor does it induce the expression of 
CD8a on CD4+ T cell clones or cord blood T cells (H. 
Yssel and H. Spits, unpublished data). Recently, Zurawski 
et al. have shown that IL-13 was able to competitively in­
hibit binding of IL-4 to IL-4R on TF-1 cells but not on 
Ba/F3 cells that were transfected with the IL-4R-binding 
protein (82). In addition, an IL-4 mutant protein which 
binds, but does not activate the IL-4 receptor, has antago­
nistic activities and blocked both IL-4- and IL-13-induced 
biologic activities (82). These results indicate that IL-4R 
and IL-13R share a receptor component necessary for sig­
nal transduction which is not the IL-4R-binding protein. 
The multiple biologic activities of IL-13 on monocytes in­
dicate that this factor could play an important role in in­
flammatory, allergic, and immunoregulatory processes.
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